ProCE Banner Activity

NSCLC Biomarkers: Current Landscape and Future Perspectives for Precision Medicine

Watch this on-demand Webcast capturing a live CCO Webinar to gain expert perspectives from a medical oncologist and pathologist on biomarker testing and personalized therapy in NSCLC.

Released: October 05, 2020

Expiration: October 04, 2021

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Sanjay Mukhopadhyay

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Merck Sharp & Dohme Corp.

Learning Objectives

  • Assess new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca and funds for research support paid to his institution from Celgene, Genentech/Roche, Merck, Novartis, and OncoMed.

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Sanjay Mukhopadhyay, MD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.